A new FDA Fast Track designation for Zambon
The designation is for L CsA i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company
News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.